Find your next paid study

Corvus Pharmaceuticals, Inc.NCT06561048

Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5 more

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitum…

Novartis PharmaceuticalsNCT04104776

Lymphoma, B-CellLymphoma, T-Cell

An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5…

Step Pharma, SASNCT05463263

Phase 2

Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have …

T-cell LymphomaGraft Versus Host DiseaseLymphoma, T-Cell+5 more

Jonathan BrammerNCT07356245

~$10 – $7,500

A Tissue Repository for the Collection of Samples From Patients With Cutaneous T Cell Lymphoma and Healthy Volunteers

This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T…

Lymphoma, T-Cell, CutaneousLymphomatoid PapulosisSézary Syndrome

Columbia UniversityNCT02840747

~$10 – $750

Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL

This is an open-label, Phase 1/2a, dose-finding study with an initial phase 1 portion, articulated in four separate treatment arms, followed by a dedicated pha…

Lymphoma, T-Cell

University of VirginiaNCT03161223

~$10 – $6,250

Hematologic MalignancyAMLALL+8 more

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult pati…

Therapeutic Advances in Childhood Leukemia ConsortiumNCT05476770

~$10 – $7,500

Phase 2

A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r…

Lymphoma, T-Cell